AbbVie to Invest US$380 Million in North Chicago, USA
Introduction:
AbbVie has announced an investment of US$380 million to construct two active pharmaceutical ingredient (API) manufacturing facilities at its North Chicago campus in Illinois, USA.
Features:
The development involves the construction of two active pharmaceutical ingredient (API) manufacturing facilities within an existing pharmaceutical manufacturing campus. These facilities will support the production of APIs used in neuroscience and obesity treatments, where APIs serve as the core components responsible for the therapeutic effects of medicines.
The production processes will include chemical synthesis and multi-step manufacturing activities, supported by advanced manufacturing technologies, digital systems, and artificial intelligence-based solutions to enhance operational efficiency.
This expansion will contribute to increased API manufacturing capacity in the United States while also strengthening domestic production of selected pharmaceutical components.
Construction activities are scheduled to begin in 2026, with operations expected to commence by 2029.
Specifications:
| Name | AbbVie |
| Type | New Construction |
| Budget | US$380 million |
| Year | 2029 |
